Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ABBV-368 + ABBV-927 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-368 | ABBV368|ABBV 368 | OX40 Antibody 14 | ABBV-368 is an activating monoclonal antibody to the T-cell receptor, TNFRSF4 (OX40, CD134) (NCI Drug Dictionary). | |
ABBV-927 | ABBV 927|ABBV927 | CD40 Antibody 14 | ABBV-927 is a monoclonal antibody to TNFRSF5 (CD40), which mimics the binding of the ligand, CD40LG (CD40L), to stimulate proliferation of T-cells and enhance an anti-tumor response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03893955 | Phase I | ABBV-368 + ABBV-927 + Nab-paclitaxel ABBV-368 + ABBV-927 ABBV-368 + ABBV-927 + Budigalimab ABBV-927 + Budigalimab + Carboplatin ABBV-927 + Carboplatin ABBV-368 + ABBV-927 + Carboplatin | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | FRA | ESP | AUS | 2 |